Drug Profile
Research programme: benzopyran-based therapeutics - Kazia Therapeutics
Alternative Names: CS-6; SBP therapeutics - Kazia Therapeutics; Super-benzopyran compounds - Kazia Therapeutics; Trilexium (Trx) analogues - Kazia Therapeutics; Trx-2 - Kazia Therapeutics; TRXE-0025; TRXE-009; TRXE-009-1; TRXE-025Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Novogen
- Developer Kazia Therapeutics; Weill Cornell Medical College
- Class Benzopyrans; Small molecules
- Mechanism of Action Cell cycle inhibitors; EIF 2 kinase inhibitors; Electron transport chain complex protein inhibitors; Glucuronidase modulators; JNK mitogen-activated protein kinase modulators; NADH oxidase inhibitors; Stem cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Brain cancer; Brain disorders; Brain injuries; Facioscapulohumeral muscular dystrophy; Glioblastoma; Malignant melanoma; Mucopolysaccharidosis III; Neuroblastoma; Ovarian cancer; Prostate cancer
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Glioblastoma in Australia (IV)
- 28 Mar 2023 Discontinued - Preclinical for Glioblastoma in USA (IV)
- 28 Mar 2023 Discontinued - Preclinical for Malignant melanoma in Australia (Parenteral)